Restrictive Cardiomyopathy (RCM) Cell Models for Research

Restrictive cardiomyopathy (RCM) is a rare form of heart muscle disease characterized by impaired ventricular filling with preserved systolic function. The exact prevalence is unknown, but it accounts for approximately 2-5% of all cardiomyopathies in adults (WHO, 2023). RCM can affect individuals of all ages, with a bimodal distribution: children often present with a more severe phenotype, while adults may have a slower progression. The 5-year mortality rate is high, with estimates ranging from 30% to 50% in symptomatic patients (NCI, 2023). The disease can be idiopathic, familial, or secondary to systemic disorders such as amyloidosis, sarcoidosis, or hemochromatosis. The clinical impact is significant, as RCM often leads to heart failure, arrhythmias, and sudden cardiac death. There is currently no cure, and treatment is largely supportive, making the development of effective therapies a critical unmet need.

RCM is an ideal model for studying the molecular mechanisms of diastolic dysfunction and myocardial fibrosis. The disease is genetically heterogeneous, with mutations in sarcomeric, cytoskeletal, and desmosomal genes. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the ClinVar database, provide valuable information on gene expression and variant pathogenicity. However, the rarity of RCM poses challenges for clinical studies, making in vitro models essential. Gene-edited cell models, such as CRISPR knockout and knock-in lines, allow researchers to dissect the functional consequences of specific mutations in a controlled environment. These models can be used to study disease mechanisms, screen for potential therapeutics, and validate novel drug targets, thereby accelerating the translation of basic research into clinical applications.

Although RCM is not a cancer, the term 'carcinogenic' is not applicable. Instead, we focus on the pathogenic pathways that lead to diastolic dysfunction and fibrosis. The major pathways include:

• • Sarcomeric dysfunction: Mutations in sarcomeric proteins (e.g., TNNT2, MYH7, TNNI3) disrupt the actin-myosin interaction, leading to impaired relaxation and increased stiffness.
• • Cytoskeletal abnormalities: Mutations in desmin (DES) or filamin C (FLNC) cause disruption of the intermediate filament network, affecting cellular integrity and signal transduction.
• • Calcium handling defects: Alterations in calcium homeostasis, often due to mutations in genes encoding calcium-handling proteins (e.g., PLN, RYR2), lead to impaired relaxation and arrhythmias.
• • Fibrotic remodeling: Chronic activation of transforming growth factor-beta (TGF-β) signaling promotes fibroblast proliferation and extracellular matrix deposition, contributing to myocardial stiffness.

Data derived from TCGA (not applicable) and COSMIC (not applicable) – actually, these are from ClinVar and literature. For accuracy, we note that frequencies are based on familial cohorts and may vary.

Several signaling networks are deregulated in RCM:

• • TGF-β signaling: Key nodes include TGF-β1, TGF-β receptor I/II, SMAD2/3, and SMAD4. Activation leads to fibrosis.
• • MAPK/ERK pathway: Mutations in sarcomeric genes can activate ERK1/2, promoting hypertrophy and apoptosis.
• • PI3K/AKT pathway: Altered signaling affects cell survival and growth.
• • Calcium/calcineurin/NFAT pathway: Increased intracellular calcium activates calcineurin, which dephosphorylates NFAT, leading to hypertrophic gene expression.
• • Autophagy and proteostasis: Impaired autophagy, as seen in BAG3 mutations, leads to protein aggregation and cellular toxicity.

Organoids, such as cardiac organoids derived from iPSCs, offer a more physiologically relevant 3D environment and can recapitulate aspects of RCM, including fibrosis and impaired contractility. They are valuable for drug testing and disease modeling.

• • Patient-derived xenografts (PDX): Not applicable for RCM as it is not a cancer.
• • Genetically engineered mouse models (GEMM): Mice with knock-in mutations in TNNT2 (e.g., R92W) or MYH7 (e.g., R403Q) recapitulate RCM phenotypes, including diastolic dysfunction and fibrosis.
• • Induced models: Administration of drugs (e.g., doxorubicin) or transverse aortic constriction can induce cardiac remodeling, but these are not specific to RCM.
• • Zebrafish models: Transgenic zebrafish with sarcomeric mutations have been used to study cardiac function and screen for therapeutic compounds.

Gene-edited cell models are powerful tools for studying RCM. CRISPR-Cas9 technology allows the generation of isogenic cell lines with precise genetic modifications, such as:

• • Knockout lines: For example, a TNNT2 knockout in AC16 cells can be used to study the loss of function of troponin T.
• • Knock-in lines: Introducing a specific point mutation (e.g., TNNT2 R92W) into a wild-type background to model the disease.
• • Reporter lines: Tagging a gene with a fluorescent protein (e.g., GFP) to track protein localization and expression.

These models are commercially available from various sources and are sequence-verified, ensuring high quality and reproducibility. They accelerate research by providing consistent, isogenic backgrounds, reducing variability, and enabling high-throughput screening.

Gene-edited cell lines are essential for functional genomics studies. For example, a TNNT2 knockout line can be used to identify downstream targets and pathways affected by troponin T loss. Similarly, a MYH7 knock-in line can be used to study the effects of specific mutations on myosin function and cellular contractility. These models allow researchers to validate candidate genes from genome-wide association studies (GWAS) and to dissect the molecular mechanisms underlying RCM.

Isogenic pairs, such as a wild-type and a mutant cell line, are ideal for drug screening. By comparing the response of mutant cells to wild-type cells, researchers can identify compounds that specifically target the mutant phenotype. For example, a TNNT2 R92W knock-in line can be used to screen for drugs that improve calcium handling or myofilament sensitivity. Additionally, gene-edited cells can be used to model drug resistance, as seen in cancer, but for RCM, this may involve resistance to therapies that target fibrosis or calcium handling.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of RCM cells but not normal cells. This approach can reveal novel therapeutic targets and biomarkers. For example, a screen using a DES knockout line might identify genes that, when silenced, cause cell death specifically in DES-deficient cells. Such targets could be exploited for drug development. Additionally, gene-edited cells can be used to identify secreted proteins that serve as biomarkers for disease progression.